LET IT FLOW: scaling-up continuous cell-manufacture capability for allogeneic therapies

Healthcare costs, manufacturing inefficiencies and population growth contributed to a substantial increase in the number of individuals struggling with dangerous or chronic diseases. For instance, the IDF Diabetes Atlas (2021) reports that 10.5% of the adult population (20-79 years) has diabetes, with almost half unaware that they are living with the condition. By 2050, society will need a healthcare system capable of providing 10bn people with accessible and cost-effective diagnostics and treatments.

C> has the potential to solve this global challenge. C> treatments Care transforming how metabolic diseases, neurology and infectious diseases are treated and potentially cured, significantly changing healthcare outcomes.

However, current cell-manufacturing technologies in this nascent field are inefficient and expensive for the scale this market needs to achieve. The first autologous therapy was approved by the FDA in 2017\. By 2022, there were only 27 FDA-approved C>s, representing approximately 8% of the 340 approved biologics, only a small fraction of conventional drugs. This creates a substantial need for innovative solutions to provide a scalable and efficient cell-manufacturing process.

To solve this need, CellulaRevolution Ltd (CellRev) has developed a highly innovative bioreactor system allowing continuous manufacture of adherent cells. CellRev's innovation will expedite the scaling up of allogeneic cell therapies, which will help address health access treatment of dangerous and chronic diseases in the UK and globally.

This is a truly unique and breakthrough solution in cell-culture that can potentially manufacture 45x current yields, significantly reduce consumable usage by substituting the current single-use batch culture tech, and lower capital & operating costs by 94%.